Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Safety, Immunogenicity and Preliminary Efficacy of mKRAS Antigen-Loaded eDCs (CAT-101) Monotherapy or Plus Tislelizumab (Anti-PD-1 mAb) in KRAS-G12C/D/R/V-Mutated Advanced Pancreatic Cancer and Other Solid Tumors

NCT07396090 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07396090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07396090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Safety, Immunogenicity and Preliminary Efficacy of mKRAS Antigen-Loaded eDCs (CAT-101) Monotherapy or Plus Tislelizumab (Anti-PD-1 mAb) in KRAS-G12C/D/R/V-Mutated Advanced Pancreatic Cancer and Other Solid Tumors
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 20, 2026
Completion date
December 31, 2026
Enrollment
13 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor